George Tonn
Denali Therapeutics (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Chemokine receptors and signaling, Pharmacogenetics and Drug Metabolism, Pregnancy and preeclampsia studies, Diabetes Treatment and Management
Most-Cited Works
- → The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America(2009)305 cited
- → AMG 837: A potent, orally bioavailable GPR40 agonist(2011)130 cited
- → SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase(2006)126 cited
- → Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3(2007)104 cited
- → AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents(2011)94 cited
- → DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers(2019)73 cited
- → Tetrahydroquinoline derivatives as CRTH2 antagonists(2009)47 cited
- → Selective and Brain‐Permeable Polo‐like Kinase‐2 (Plk‐2) Inhibitors That Reduce α‐Synuclein Phosphorylation in Rat Brain(2013)47 cited
- → Bioactivation of Sitaxentan in Liver Microsomes, Hepatocytes, and Expressed Human P450s with Characterization of the Glutathione Conjugate by Liquid Chromatography Tandem Mass Spectrometry(2013)44 cited
- → Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists(2007)43 cited